American College of Cardiology Urges Heart Attack, Stroke Patients to Seek Medical Help

Through its CardioSmart patient initiative, the American College of Cardiology has issued guidance to encourage patients experiencing a heart attack or stroke to call 911.  While hospitals across the United States are experiencing an influx of COVID-19 patients, clinicians are reportedly seeing fewer patients going to emergency rooms for heart attack or stroke. Experts worry that patients who need critical care are delaying their treatment over concerns about the novel coronavirus.

“Due to fears of contracting COVID-19 or taking up space in hospitals, patients experiencing a heart attack or stroke are delaying their essential care, causing a new public health crisis,” said Martha Gulati, MD, FACC, editor-in-chief of CardioSmart.org. “Hospitals and catheterization labs are still treating heart attack and stroke, not just COVID-19, and are taking the utmost precautions to ensure that the novel coronavirus not be spread. The faster a patient is treated, the higher the outcome of survival and lower the risk for complications. No patient should delay their care.”

A new CardioSmart infographic, “Coronavirus and Your Heart: Don’t Ignore Heart Symptoms,” encourages patients to pay close attention to heart attack or stroke symptoms, particularly if they have a pre-existing heart condition, and call 911 immediately if they believe they’re having a heart attack or stroke. The infographic details common heart attack and stroke symptoms and ensures hospitals are taking steps to protect them from COVID-19. The infographic also encourages patients to continue routine heart care to ensure they stay healthy, which may be accomplished through telehealth (remote or virtual visit) or a phone call with their clinician.

“We encourage clinicians to widely distribute these tools to their patients. Make sure that patients know when telehealth is an appropriate option, and when they should call 911 instead,” Gulati said. “Clinicians should work with patients to ensure medication adherence, and always continue to advocate for heart-healthy measures that can be taken even in times of self-isolation and social distancing.”

CardioSmart serves as the ACC’s patient engagement initiative. Reviewed by experts in the CardioSmart COVID-19 Response Work Group, the new infographic joins the full collection of ACC COVID-19 resources, including clinical bulletins, journal articles, patient summaries and more. For more information about how COVID-19 affects patients with pre-existing heart conditions, and to download the full infographic, visit the CardioSmart COVID-19 Hub.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”